(S)-2-(1 ,6,7,8-tetrahydro-2h-indeno[5,4-b]furan-8-yl)ethylamine (Cas 196597-81-6)

We are instrumental in manufacturing, exporting, trading and supplying ((S)-2-(1 ,6,7,8-Tetrahydro-2H-Indeno[5,4-B]Furan-8-Yl)Ethylamine (CAS 196597-81-6) in Minhang, Shanghai, China which is a key intermediate for synthetizing Ramelteon, a MT1 and MT2 melatonin receptor selective agonist.
Previously, sleep agents bind to GABAA receptors which are associated with anxiolytic, myorelaxant, and amnesic effects, such as with drugs like , eszopiclone, and . As the first in a new class of sleep agents, Ramelteon selectively binds to the MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN). It was developed by Takeda Pharmaceuticals North America with the trade name Rozerem, and was approved by the U.S. Food and Drug Administration (FDA) on July 4th, 2005 for long-term use. It can be used for insomnia, delayed sleep onset in particular. There is no proof showing that Ramelteon produces dependence and any potential for abuse. What's more, while there is withdrawal and rebound insomnia typically with GABA modulators, it is not shown in ramelteon. Ramelteon can also be used for the treatment of Delayed sleep phase syndrome. Ramelteon was proven by practice to be associated with a lower risk of delirium (3% vs 32%; Pa =a .003). According to Chakraborti, D; Tampi, D. J.; Tampi, R. R. (2014) ("Melatonin and Melatonin Agonist for Delirium in the Elderly Patients").